VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research report sent to investors on Wednesday morning,Benzinga reports. They currently have a $5.75 price target on the stock.

Separately, BTIG Research started coverage on VYNE Therapeutics in a research report on Monday, November 18th. They issued a “buy” rating and a $8.00 price objective for the company.

VYNE Therapeutics Price Performance

Shares of VYNE Therapeutics stock opened at $2.52 on Wednesday. The firm has a 50 day simple moving average of $2.81 and a 200 day simple moving average of $2.45. VYNE Therapeutics has a fifty-two week low of $1.57 and a fifty-two week high of $4.30. The firm has a market cap of $37.17 million, a P/E ratio of -2.93 and a beta of 1.28.

Insiders Place Their Bets

In related news, Director Patrick G. Lepore purchased 15,000 shares of the business’s stock in a transaction dated Wednesday, January 15th. The shares were bought at an average price of $2.92 per share, with a total value of $43,800.00. Following the purchase, the director now directly owns 51,472 shares in the company, valued at $150,298.24. This trade represents a 41.13 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this link. Company insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On VYNE Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in VYNE. Acorn Capital Advisors LLC bought a new position in VYNE Therapeutics during the fourth quarter worth about $1,531,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of VYNE Therapeutics in the 4th quarter valued at approximately $823,000. Adage Capital Partners GP L.L.C. bought a new position in VYNE Therapeutics during the 4th quarter worth approximately $516,000. Bridgeway Capital Management LLC acquired a new position in VYNE Therapeutics during the fourth quarter valued at approximately $124,000. Finally, XTX Topco Ltd acquired a new position in VYNE Therapeutics during the fourth quarter valued at approximately $70,000. Institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.